Skip to content
Canadian orders above $200 ship free · Dispatched from Canadian stock

Buy Ipamorelin in Canada

Ipamorelin in Canada

Ipamorelin comes as lyophilised powder in 10 mg vials, HPLC tested from batch to batch and dispatched out of Canadian stock for laboratory research only.

Format
Size
$62.00$6.20/mg
Dispatched from Canadian stock

Buy more, pay less per vial

Add 2 more to save 4%

Frequently bought together

At a glance
Also known as
Ipamorelin acetate · NNC 26-0161 · IPA
Class
Growth hormone secretagogue (ghrelin receptor agonist)
Form
Lyophilised powder supplied in 10 mg vials
Sizes
10 mg
Storage, dry
−20 °C, dry and dark
Storage, mixed
2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
BAC water per size
10 mg: 2 mL

What is Ipamorelin?

Both suppliers and the literature classify Ipamorelin as a growth hormone secretagogue (ghrelin receptor agonist). The published work spans rat, human and primary rat pituitary cell models. The same material appears under several names in the literature, among them Ipamorelin acetate, NNC 26-0161 and IPA. Its recorded sequence is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2 (as given by Raun et al. 1998), and it contains non-natural amino acids (Aib, D-2-naphthylalanine). Of the 8 references below, one is a controlled human trial. It comes as lyophilised powder in 10 mg vials, kept in Canadian stock for laboratory research. It is not a medicine and is not for use in humans or animals.

What the research shows

StudyModelDose usedDurationFinding
Beck DE et al.2014 · Int J Colorectal Dis · PMID 25331030Human, randomised, double-blind, placebo-controlled phase 2 trial in adults after bowel resection (n=114 in the safety population)0.03 mg/kg by intravenous infusion, twice dailyPostoperative day 1 to 7 or hospital dischargeTreatment-emergent adverse events occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group. Median time to the first tolerated solid meal was 25.3 h vs 32.6 h (p = 0.15), and there were no significant differences in the key or secondary efficacy analyses.
Gobburu JV et al.1999 · Pharm Res · PMID 10496658Human, healthy male volunteers, dose-escalation pharmacokinetic study (8 subjects at each of 5 dose levels)4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg infused over 15 minutesSingle infusionPharmacokinetics were dose-proportional, with a terminal half-life of 2 hours. Each dose produced a single episode of growth hormone release peaking at 0.67 hours, then declining to negligible levels.
Raun K et al.1998 · Eur J Endocrinol · PMID 9849822Primary rat pituitary cells, anaesthetised rats and conscious swineNot stated in the abstract (dose-response; ED50 of 80 nmol/kg in rats and 2.3 nmol/kg in swine)Acute dosingIpamorelin released growth hormone with potency and efficacy similar to GHRP-6. In swine it did not affect FSH, LH, prolactin or TSH, and unlike GHRP-6 and GHRP-2 it did not raise ACTH or cortisol, even at doses more than 200-fold above the ED50.
Venkova K et al.2009 · J Pharmacol Exp Ther · PMID 19289567Rat, postoperative ileus model (laparotomy and intestinal manipulation)0.01–1 mg/kg intravenous bolusSingle dose, or 2 days of repeated dosing (four doses a day at 3-h intervals)A single 1 mg/kg dose shortened the time to first bowel movement. Repeated dosing at 0.1 or 1 mg/kg significantly increased cumulative faecal pellet output, food intake and body weight gain over 48 h.
Greenwood-Van Meerveld B et al.2012 · J Exp Pharmacol · PMID 27186127Rat, postoperative ileus model, plus isolated gastric fundus tissue0.014–0.14 µmol/kg intravenous; 1 µM in the organ bathSingle doseAfter surgery, 78% of a test meal remained in the stomach of vehicle-treated rats compared with 52% after ipamorelin 0.014 µmol/kg (P < 0.05). Ipamorelin also reversed the loss of gastric muscle contractility caused by the surgery.
Johansen PB et al.1999 · Growth Horm IGF Res · PMID 10373343Rat, adult females18, 90 and 450 micrograms/day, s.c., split over three injections a day15 daysLongitudinal bone growth rose dose-dependently from 42 micrometres/day with vehicle to 44, 50 and 52 micrometres/day (P < 0.0001), with a dose-dependent gain in body weight. Total IGF-I, IGFBPs and serum bone-turnover markers did not change.
Svensson J et al.2000 · J Endocrinol · PMID 10828840Rat, young adult females (n=7 for ipamorelin)0.5 mg/kg per day, continuous s.c. infusion by osmotic minipump12 weeksIpamorelin, GHRP-6 and GH all increased body weight and tibial and vertebral bone mineral content. Bone mineral content corrected for body weight was unchanged, and the authors attributed the increase to larger bone dimensions rather than denser bone.
Andersen NB et al.2001 · Growth Horm IGF Res · PMID 11735244Rat, 8-month-old females given the glucocorticoid methylprednisolone100 micrograms/kg s.c., three times daily3 monthsGiven with the glucocorticoid, ipamorelin significantly increased maximum tetanic tension of the calf muscles, and periosteal bone formation rate was four-fold higher than with the glucocorticoid alone.

What these studies don't show: The controlled evidence is genuine, yet it belongs to one particular setting. The people enrolled, the measures taken and the length of follow-up each set a limit on what the findings can mean. The results apply to the setting studied and no further. An HPLC trace reports what is present, and that is a different matter from efficacy.

Every study links to its PubMed record. See all Ipamorelin studies in the research library →

Ipamorelin price in Canada: 10mg vial

Buy Ipamorelin in Canada in a 10mg vial and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.

SizePricePer mg
10 mg$62.00$6.20/mg

Starter kit

Is Ipamorelin available in Canada?

No Ipamorelin-containing product carries a Drug Identification Number in Canada. Health Canada has reached no finding on it, since it has never been submitted for one. Borealis Peptides keeps it strictly for in-vitro research and provides it for no use in a living subject. How Health Canada treats research peptides →

Side effects reported in studies

Every statement here is linked to the study that recorded it. Tolerability observations from the cited papers appear below in the authors' own words. Human work on this scale does not establish a safety profile. Read more →

Doses used in studies

Read more →

Ipamorelin FAQ

What is Ipamorelin?

Chemically, Ipamorelin is grouped as a growth hormone secretagogue (ghrelin receptor agonist). Its published record is drawn from rat, human and primary rat pituitary cell work. Borealis Peptides provides it as lyophilised powder in 10 mg vials for in-vitro laboratory research. It holds no medicine authorization and is not for use in any living subject. The table on this page sets out each study, its model and its reported result.

Where can I buy Ipamorelin in Canada?

It is dispatched within Canada from the stock we keep, in 10 mg vials. Nothing goes out without HPLC confirmation of identity and purity for that batch. Borealis Peptides takes research orders only and ships to research and business addresses. HPLC is run on each batch, and the certificate you receive points to the batch you were sent.

Is Ipamorelin legal in Canada?

No Ipamorelin-containing product carries a Drug Identification Number in Canada. Health Canada has reached no finding on it, since it has never been submitted for one. Kept by Borealis Peptides for in-vitro research, it is supplied for use in no living subject. Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, so we read it as what the material is stocked for, not an approval to use it.

How much Ipamorelin should I use?

There is nothing to give. This site holds no protocol, no schedule and no reconstitution volume. The quantities in the cited studies belong to those studies and the models they ran in; they appear so that the evidence can be weighed rather than accepted on trust.

What human evidence is there for Ipamorelin?

One of the 8 cited studies is a controlled trial in people, and the remainder are animal or cell work. Each row lists its model, the amount used and the authors' reported outcome, so every study can be weighed on its own terms instead of through a summary.

How is Ipamorelin stored?

The dry powder rests at −20 °C, kept out of the light. In solution it is held at 2–8 °C. The lyophilised powder withstands ambient temperature in transit, so it travels without ice and goes into the fridge on arrival. Light and repeated warming cause more harm than the journey does.

How is the purity of Ipamorelin confirmed?

HPLC testing is done on every batch before sale, and the certificate points to the batch in your vial rather than to the product as a whole. Holding on to that batch number alongside your records is what lets an observation be reproduced later. Certificates can be supplied on request.

How does Ipamorelin compare with CJC-1295 + Ipamorelin and CJC-1295 (no DAC)?

They are not interchangeable, and this page claims no preference among them. CJC-1295 + Ipamorelin and CJC-1295 (no DAC) have 8 cited studies and 6 cited studies on their page against 8 here. The comparison that helps is between the two study tables and the models behind them.

Why is Ipamorelin named in a Health Canada advisory?

Because it was one of the peptides seized from sellers offering unauthorized injectable products online. That advisory deals with material sold for people to inject without authorization. Everything Borealis Peptides ships is research material for in-vitro work; nothing is sold for injection or for any use in a person, the distinction the advisory rests on.

Compare with